Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Neovasc files for CE Mark for Tiara TA Transapical system » 09:43
05/27/20
05/27
09:43
05/27/20
09:43
NVCN

Neovasc

$2.94 /

+ (+0.00%)

Neovasc announced that…

Neovasc announced that the company has filed for CE Mark for its Tiara TA Transapical mitral valve replacement system. Mitral Valve disease is one of the most common forms of heart disease that affects millions of patients worldwide. Traditional heart valve replacement surgery requires patients to be placed on a heart-lung bypass machine and results in lengthy recovery time. The Tiara TA transapical mitral valve replacement system uses a percutaneous or "key-hole" incision in the chest to completely replace the native mitral valve and avoids the need for heart-lung bypass. The less invasive approach may allow for more patients to be treated and more rapid recovery. In April, the European Parliament voted overwhelmingly to extend the Medical Device Directive by one year rather than to transition to a new approval process known and the European Medical Device Regulation.

ShowHide Related Items >><<
NVCN Neovasc
$2.94 /

+ (+0.00%)

NVCN Neovasc
$2.94 /

+ (+0.00%)

05/08/20 H.C. Wainwright
Neovasc price target lowered to $5 from $9 at H.C. Wainwright
04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Noble Capital
Neovasc initiated with an Outperform at Noble Capital
10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
NVCN Neovasc
$2.94 /

+ (+0.00%)

Hot Stocks
Neovasc seeing return of elective procedures, progress on capital structure » 17:06
05/26/20
05/26
17:06
05/26/20
17:06
NVCN

Neovasc

$2.94 /

+0.28 (+10.53%)

Neovasc announced a…

Neovasc announced a corporate update on its progress towards its value creation strategies. Fred Colen, Chief Executive Officer of Neovasc, commented, "Today's corporate update is a testament to the teamwork and commitment of our employees, physician partners and regulators around the globe. We would like to thank the investors who have given us the opportunity to advance our programs and we are thrilled to continue to advance our value creation strategies." We are beginning to see a return of elective procedures in Germany and other European markets. After a marked slowdown that began in March, Reducer implant rates in Germany, where the company has a direct sales team and NUB Status 1 designation for reimbursement, are once again approaching pre-COVID-19 levels. As previously discussed, the company is aware of the backlog of potential Reducer patients related to COVID-19 and the reduction in elective procedures in select European markets and we look forward to continued acceleration. The National Institute for Health and Care Excellence Interventional Procedures Programme in the U.K. has invited Neovasc to participate in guidance development for Reducer treatment of refractory angina. Neovasc is honored to be considered for review by NICE and we look forward to further collaboration as we establish the value of Reducer therapy in the United Kingdom. In the United States, the Reducer FDA Pre-Market Approval milestones continue to progress, with our "100-day Meeting" recently completed. The Company has applied for CE Mark Approval under the Medical Device Directive for the Tiara TA transapical mitral valve replacement system. The Company is working interactively with our Notified Body in Europe, to advance our submission. We continue to make progress with our transfemoral Tiara TF mitral valve replacement system program with the completion of several recent animal implants. We remain focused on a first-in-human implant towards the end of the year. Following the retirement of our 2017 notes, the recently announced financing of approximately $5M will enable the Company to support ongoing operations under terms more favorable to the Company, including the removal of the particularly onerous provisions that have challenged our capital structure since 2017. The Company believes our revamped capital structure will substantially improve the Company's ability to raise additional equity capital to fund the company to its critical milestones in 2020 and early 2021.

ShowHide Related Items >><<
NVCN Neovasc
$2.94 /

+0.28 (+10.53%)

NVCN Neovasc
$2.94 /

+0.28 (+10.53%)

05/08/20 H.C. Wainwright
Neovasc price target lowered to $5 from $9 at H.C. Wainwright
04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Noble Capital
Neovasc initiated with an Outperform at Noble Capital
10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
NVCN Neovasc
$2.94 /

+0.28 (+10.53%)

Recommendations
Neovasc price target lowered to $5 from $9 at H.C. Wainwright » 07:27
05/08/20
05/08
07:27
05/08/20
07:27
NVCN

Neovasc

$2.58 /

+0.085 (+3.41%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Vernon Bernardino lowered the firm's price target on Neovasc to $5 from $9 and reiterates a Buy rating on the shares following the company's Q1 results. The quarter showed the company started 2020 with strong Reducer revenues in January and February and was on track to have its best revenue quarter ever until the impact of the COVID-19 pandemic became widespread in March, Bernardino tells investors in a research note. The analyst remains bullish on the prospects of Reducer, a novel catheter-based treatment for refractory angina.

ShowHide Related Items >><<
NVCN Neovasc
$2.58 /

+0.085 (+3.41%)

04/13/20
Fly Intel: Top five analyst initiations
04/13/20 Noble Capital
Neovasc initiated with an Outperform at Noble Capital
10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
Over a month ago
Initiation
Fly Intel: Top five analyst initiations » 10:26
04/13/20
04/13
10:26
04/13/20
10:26
RAPT

Rapt Therapeutics

$17.30 /

+0.5 (+2.98%)

, ALLO

Allogene Therapeutics

$22.55 /

-0.12 (-0.53%)

, CARR

Carrier Global

$14.27 /

-0.52 (-3.52%)

, TTGT

TechTarget

$21.58 /

-0.08 (-0.37%)

, NVCN

Neovasc

$1.78 /

+0.12 (+7.23%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rapt Therapeutics (RAPT) initiated with a Buy at Roth Capital. 2. Allogene Therapeutics (ALLO) initiated with a Buy at SunTrust. 3. Carrier Global (CARR) initiated with a Neutral at Citi. 4. TechTarget (TTGT) initiated with a Buy at National Securities. 5. Neovasc (NVCN) initiated with an Outperform at Noble Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
RAPT Rapt Therapeutics
$17.30 /

+0.5 (+2.98%)

04/13/20 Roth Capital
Rapt Therapeutics initiated with a Buy at Roth Capital
02/11/20 UBS
Rapt Therapeutics price target raised to $44 from $31 at UBS
11/25/19
Fly Intel: Top five analyst initiations
11/25/19 UBS
Rapt Therapeutics initiated with a Buy at UBS
ALLO Allogene Therapeutics
$22.55 /

-0.12 (-0.53%)

04/13/20 SunTrust
Allogene Therapeutics initiated with a Buy at SunTrust
04/13/20 SunTrust
Allogene Therapeutics initiated with a Buy at SunTrust
03/27/20 Roth Capital
Allogene seeing ALL trial disruption from COVID-19, says Roth Capital
03/04/20 Stifel
Allogene Therapeutics initiated with a Hold at Stifel
CARR Carrier Global
$14.27 /

-0.52 (-3.52%)

04/13/20 Citi
Carrier Global initiated with a Neutral at Citi
04/09/20
Fly Intel: Top five analyst initiations
04/09/20 Morgan Stanley
Carrier Global initiated with an Equal Weight at Morgan Stanley
04/09/20 Barclays
Carrier Global initiated with an Equal Weight at Barclays
TTGT TechTarget
$21.58 /

-0.08 (-0.37%)

04/13/20 National Securities
TechTarget initiated with a Buy at National Securities
11/07/19 Lake Street
TechTarget price target raised to $29 from $24 at Lake Street
05/09/19 Lake Street
TechTarget target raised to $24 after Q1 upside at Lake Street
05/09/19 Craig-Hallum
TechTarget upgraded to Buy from Hold at Craig-Hallum
NVCN Neovasc
$1.78 /

+0.12 (+7.23%)

04/13/20 Noble Capital
Neovasc initiated with an Outperform at Noble Capital
10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
Initiation
Neovasc initiated with an Outperform at Noble Capital » 09:16
04/13/20
04/13
09:16
04/13/20
09:16
NVCN

Neovasc

$1.66 /

+0.11 (+7.10%)

Noble Capital initiated…

Noble Capital initiated coverage of Neovasc with an Outperform rating and $15 price target.

ShowHide Related Items >><<
NVCN Neovasc
$1.66 /

+0.11 (+7.10%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
Over a quarter ago
Hot Stocks
Neovasc expects current cash to last until August » 09:14
03/04/20
03/04
09:14
03/04/20
09:14
NVCN

Neovasc

$2.76 /

+0.04 (+1.47%)

The company said,…

The company said, "The company had $14.1M cash on hand following the early January capital raise, and current cash is expected to last us until August of this year. Significantly, this capital will last beyond the maturity date of the remaining 2017 convertible notes on May 17, 2020. Retiring or amending those notes will be a positive step forward for the Company."

ShowHide Related Items >><<
NVCN Neovasc
$2.76 /

+0.04 (+1.47%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
Hot Stocks
Neovasc targets obtaining CE Mark for TA Tiara by 2021 or earler » 09:13
03/04/20
03/04
09:13
03/04/20
09:13
NVCN

Neovasc

$2.76 /

+0.04 (+1.47%)

The company said,…

The company said, "Eighty-two patients have been treated to date with transapical Tiara, and after extensive analysis of all Clinical data, the company believes there is sufficient evidence from the Tiara I and II clinical studies to support a CE Mark. Management plans to submit for CE Mark under the new European MDR regulations in 2020 and is targeting obtaining a CE Mark for the TA Tiara by 2021 or earlier. Regarding the next generation, transfemoral/trans-septal Tiara, the design has been frozen, and we are on track for clinical trials, including a first-in-human implant, by the end of 2020. Neovasc is targeting the large unmet need for mitral valve regurgitation and optimal treatment will require a variety of treatment options. The TF/TS Tiara features a unique "D shape" which mimics the native anatomy and is designed to avoid left ventricular outflow tract obstruction. Additionally, the TF/TS Tiara features full retrievability of the device after the atrial and ventricular portions of the valve have been deployed, until the point of final release. This key feature should further reduce implant risk for the patient, which combined with longer term functional benefits may provide many mitral valve regurgitation patients a new treatment option."

ShowHide Related Items >><<
NVCN Neovasc
$2.76 /

+0.04 (+1.47%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
Hot Stocks
Neovasc expects further clarity on PMA application for Reducer in 2020 » 09:11
03/04/20
03/04
09:11
03/04/20
09:11
NVCN

Neovasc

$2.76 /

+0.04 (+1.47%)

The company said,…

The company said, "The Company is increasingly bullish on Reducer and remains focused on capitalizing on the improving market dynamics for the device. Management believes the landscape for the treatment of refractory angina and ischemia is changing favorably. Focus in Interventional Cardiology is shifting towards the treatment of Angina for chronic ischemic patients either with or without coronary artery obstruction. There is growing interest in physiology driven by new diagnostic tools and new European Guidelines, to differentiate between angina caused by obstructive coronary artery disease or microvascular disease. The increasing rate of diagnosis of microvascular disease provides support for the treatment of refractory angina with the Reducer in appropriate patients. Additionally, Neovasc believes it has established the partnerships needed in Europe and is making significant progress selling Reducer in Germany with a newly expanded sales force, as evidenced by strong double-digit revenue growth. The company is in on-going discussions with FDA regarding the PMA application for the Reducer filed in late December. We are encouraged with the feedback to date and will continue to work with the FDA during the review process. We expect further clarity during the course of 2020."

ShowHide Related Items >><<
NVCN Neovasc
$2.76 /

+0.04 (+1.47%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
Hot Stocks
Neovasc says Reducer featured in peer reviewed EuroIntervention » 09:08
03/03/20
03/03
09:08
03/03/20
09:08
NVCN

Neovasc

$2.72 /

+0.12 (+4.62%)

Neovasc announced the…

Neovasc announced the Neovasc Reducer was featured in the peer reviewed publication EuroIntervention, the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions and highlighted in PCR Online. In the study published in EuroIntervention, "Coronary sinus Reducer implantation results in improved oxygen kinetics at cardiopulmonary exercise test in patients with refractory angina," in patients with obstructive coronary artery disease suffering from chronic refractory angina, treatment with coronary sinus Reducer implantation was associated with objective improvement in exercise capacity and oxygen kinetics tested by cardiopulmonary exercise testing as well as improvement in angina symptoms and quality of life. Patients with chronic refractory angina were treated with Reducer implantation at 2 medical centers: the Antwerp Cardiovascular Center in Belgium and the Tel Aviv Medical Center in Israel. An additional case report published in PCR Online entitled, "Coronary sinus reducer for microvascular angina," highlighted the successful implantation of the Reducer in a 61 year-old man with a history of coronary artery stenting, hypertension, type-2 diabetes and recurrent episodes of CCS class III-IV angina despite having non-obstructive coronary artery disease. Cardiac microcirculation testing revealed microvascular ischemia despite patent coronary arteries. The patient was treated with a Reducer and demonstrated objective improvement in microvascular coronary blood flow. He became asymptomatic in the weeks following the procedure.

ShowHide Related Items >><<
NVCN Neovasc
$2.72 /

+0.12 (+4.62%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
Conference/Events
SVB Leerink to hold a conference » 04:55
02/27/20
02/27
04:55
02/27/20
04:55
ABBV

AbbVie

$88.40 /

-0.73 (-0.82%)

, BBIO

BridgeBio

$32.67 /

+0.72 (+2.25%)

, CYAD

Celyad

$9.78 /

-0.17 (-1.71%)

, DCPH

Deciphera

$54.35 /

+0.495 (+0.92%)

, FULC

Fulcrum Therapeutics

$18.50 /

+2.28 (+14.06%)

, GH

Guardant Health

$81.52 /

+5.75 (+7.59%)

, IMVT

Immunovant

$14.87 /

+0.015 (+0.10%)

, INGN

Inogen

$47.88 /

+5.92 (+14.11%)

, LMAT

LeMaitre

$29.53 /

-0.35 (-1.17%)

, NUAN

Nuance

$22.27 /

+0.17 (+0.77%)

, NVCN

Neovasc

$2.70 /

+0.04 (+1.50%)

, RARE

Ultragenyx

$55.71 /

+0.88 (+1.60%)

, QURE

uniQure

$53.57 /

-0.96 (-1.76%)

, SELB

Selecta Biosciences

$4.21 /

+0.215 (+5.38%)

, VCEL

Vericel

$15.06 /

-1.645 (-9.85%)

, RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

, PODD

Insulet

$180.00 /

-17.03 (-8.64%)

, RDHL

RedHill Biopharma

$4.68 /

+0.12 (+2.63%)

, TCRR

TCR2 Therapeutics

$13.67 /

+0.36 (+2.70%)

, ORGO

Organogenesis

$4.23 /

-0.14 (-3.20%)

, OSMT

Osmotica Pharmaceuticals

$5.45 /

+0.32 (+6.24%)

, MLND

Millendo Therapeutics

$8.75 /

+0.08 (+0.92%)

, ITCI

Intra-Cellular

$22.24 /

-0.79 (-3.43%)

, IFRX

InflaRx

$4.84 /

+0.69 (+16.63%)

, STSA

Satsuma Pharmaceuticals

$26.10 /

-0.22 (-0.84%)

, MIRM

Mirum Pharmaceuticals

$16.53 /

-0.81 (-4.67%)

9th Annual Global…

9th Annual Global Healthcare Conference will be held in New York on February 25-27.

ShowHide Related Items >><<
ABBV AbbVie
$88.40 /

-0.73 (-0.82%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
BBIO BridgeBio
$32.67 /

+0.72 (+2.25%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CYAD Celyad
$9.78 /

-0.17 (-1.71%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
DCPH Deciphera
$54.35 /

+0.495 (+0.92%)

02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
02/20/20 Piper Sandler
Deciphera 20% selloff brings 'great entry point,' says Piper Sandler
01/24/20 SVB Leerink
Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink
01/22/20 Piper Sandler
Piper Sandler says 'incrementally positive' on Deciphera
FULC Fulcrum Therapeutics
$18.50 /

+2.28 (+14.06%)

12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
08/12/19 BofA
Fulcrum Therapeutics initiated with a Buy at BofA/Merrill
GH Guardant Health
$81.52 /

+5.75 (+7.59%)

02/21/20
Fly Intel: Top five analyst initiations
02/21/20 Guggenheim
Guggenheim starts Guardant Health at Buy with addressable market seen expanding
02/21/20 Guggenheim
Guardant Health initiated with a Buy at Guggenheim
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
IMVT Immunovant
$14.87 /

+0.015 (+0.10%)

02/24/20
Fly Intel: Top five analyst initiations
02/24/20 SVB Leerink
Immunovant initiated with an Outperform at SVB Leerink
02/05/20
Fly Intel: Top five analyst initiations
02/05/20 Nomura Instinet
Immunovant initiated with a Buy at Nomura Instinet
INGN Inogen
$47.88 /

+5.92 (+14.11%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
LMAT LeMaitre
$29.53 /

-0.35 (-1.17%)

10/24/19 Lake Street
Lake Street upgrades LeMaitre to Buy, boosts target to $40 from $34
10/24/19 Lake Street
LeMaitre upgraded to Buy from Hold at Lake Street
10/24/19 First Analysis
LeMaitre downgraded to Outperform from Strong Buy at First Analysis
10/14/19 First Analysis
LeMaitre upgraded to Strong Buy from Outperform at First Analysis
NUAN Nuance
$22.27 /

+0.17 (+0.77%)

01/13/20 Morgan Stanley
Morgan Stanley upgrades Nuance to Overweight on path to double-digit EPS growth
01/13/20 Morgan Stanley
Nuance upgraded to Overweight from Equal Weight at Morgan Stanley
10/02/19 Evercore ISI
Cerence initiated with an Outperform at Evercore ISI
10/01/19 Raymond James
Cerence initiated with a Strong Buy at Raymond James
NVCN Neovasc
$2.70 /

+0.04 (+1.50%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
RARE Ultragenyx
$55.71 /

+0.88 (+1.60%)

01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
11/27/19 Cowen
Ultragenyx weakness a buying opportunity, says Cowen
QURE uniQure
$53.57 /

-0.96 (-1.76%)

01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
12/09/19 H.C. Wainwright
uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright
SELB Selecta Biosciences
$4.21 /

+0.215 (+5.38%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
02/18/20 Mizuho
Selecta Biosciences price target raised to $7 from $4 at Mizuho
01/29/20
Fly Intel: Top five analyst initiations
01/29/20 Cantor Fitzgerald
Cantor starts 'under the radar' Selecta Biosciences with Overweight rating
VCEL Vericel
$15.06 /

-1.645 (-9.85%)

10/09/19 H.C. Wainwright
Vericel initiated with a Buy rating at H.C. Wainwright
08/26/19 Credit Suisse
Organogenesis reinstated with an Outperform at Credit Suisse
08/14/19 Oppenheimer
MediWound price target lowered to $7 from $15 at Oppenheimer
05/07/19 Oppenheimer
Vericel price target raised to $32 from $23 at Oppenheimer
RDUS Radius Health
$17.87 /

-0.06 (-0.33%)

11/06/19 SVB Leerink
Radius Health price target lowered to $35 from $49 at SVB Leerink
08/29/19 Citi
Radius Health upgraded to Buy from Neutral at Citi
05/30/19 Citi
Radius Health assumed with a Neutral at Citi
05/29/19 Goldman Sachs
Radius Health upgraded to Buy from Neutral at Goldman Sachs
PODD Insulet
$180.00 /

-17.03 (-8.64%)

02/26/20 Cowen
Insulet weakness a buying opportunity, says Cowen
02/26/20 Raymond James
Insulet price target lowered to $205 from $213 at Raymond James
02/26/20 Piper Sandler
Insulet should be bought on selloff from guidance, says Piper Sandler
02/19/20 Piper Sandler
New partnerships expected, but positive, for Insulet, says Piper Sandler
RDHL RedHill Biopharma
$4.68 /

+0.12 (+2.63%)

07/12/19 WBB Securities
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
03/12/19
Fly Intel: Top five analyst upgrades
03/12/19 WBB Securities
RedHill Biopharma upgraded to Buy from Hold at WBB Securities
02/27/19 H.C. Wainwright
RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright
TCRR TCR2 Therapeutics
$13.67 /

+0.36 (+2.70%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital
03/11/19
Fly Intel: Top five analyst initiations
03/11/19 SVB Leerink
TCR2 Therapeutics initiated with an Outperform at SVB Leerink
ORGO Organogenesis
$4.23 /

-0.14 (-3.20%)

01/10/20 SVB Leerink
Organogenesis initiated with an Outperform at SVB Leerink
05/02/19 Credit Suisse
Organogenesis initiated with an Outperform at Credit Suisse
04/17/19
Fly Intel: Top five analyst initiations
OSMT Osmotica Pharmaceuticals
$5.45 /

+0.32 (+6.24%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
08/12/19 Jefferies
Osmotica shares discounting late-stage pipeline, says Jefferies
06/11/19 Barclays
Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays
03/28/19 Wells Fargo
Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results
MLND Millendo Therapeutics
$8.75 /

+0.08 (+0.92%)

01/10/20 Roth Capital
Millendo Therapeutics initiated with a Buy at Roth Capital
09/16/19 Jefferies
Millendo Therapeutics assumed with a Buy at Jefferies
07/19/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
07/18/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
ITCI Intra-Cellular
$22.24 /

-0.79 (-3.43%)

02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
02/18/20 Cantor Fitzgerald
Intra-Cellular price target raised to $47 from $43 at Cantor Fitzgerald
01/31/20 JPMorgan
Intra-Cellular downgraded to Neutral on high Caplyta expectations at JPMorgan
IFRX InflaRx
$4.84 /

+0.69 (+16.63%)

07/19/19 Raymond James
InflaRx should not proceed with IFX-1 in HS, says Raymond James
06/06/19 Raymond James
ChemoCentryx price target lowered to $17 from $24 at Raymond James
06/05/19
InflaRx downgraded to Market Perform on HS study results at Raymond James
06/05/19 Piper Sandler
Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure
STSA Satsuma Pharmaceuticals
$26.10 /

-0.22 (-0.84%)

02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
10/08/19 SVB Leerink
Satsuma Pharmaceuticals initiated with an Outperform at SVB Leerink
10/08/19 Credit Suisse
Satsuma Pharmaceuticals initiated with an Outperform at Credit Suisse
MIRM Mirum Pharmaceuticals
$16.53 /

-0.81 (-4.67%)

12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
08/12/19 Raymond James
Mirum Pharmaceuticals initiated with an Outperform at Raymond James

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.